Abstract | OBJECTIVE: METHODS: A total of 101 women undergoing post-abortion treatment at our family planning clinic from October 2009 to February 2011 were recruited and divided randomly into 4 groups. They were diagnosed as abortive remnants by ultrasound and blood level of β-HCG (human chorionic gonadotrophin). Three test groups received different doses of mifepristone and one group as control. The efficacy and safety of four groups were evaluated by clinical observations, ultrasonic examinations and blood level of β-HCG. RESULTS: The effective rates of mifepristone test and control groups were 61.60% and 21.40% respectively. And there were statistical significances between two groups (P < 0.01). After a 2-week treatment, the changes of blood level of β-HCG and reduction of residual size tested by ultrasound were better than those of the control group. And there were significant statistical differences (P < 0.01). The group with high dose in short term achieved the best outcomes. After four weeks of treatment, blood level of β-HCG of test groups had no statistical significance (P > 0.05). There was statistical significance in pairwise comparison on reduction of residual size tested by ultrasound among test groups (P < 0.05). The high-dose group with achieved the largest short-term reduction. Statistical significances existed in the hemostatic time of vaginal hemorrhage and menstrual recovery between three test groups and the control group (P < 0.05). No statistical significance was found in healing time and the occurrence of adverse events among these 3 test groups (both P > 0.05). CONCLUSION:
|
Authors | Ting Zhuge, Bin Li, Zi-rong Huang |
Journal | Zhonghua yi xue za zhi
(Zhonghua Yi Xue Za Zhi)
Vol. 92
Issue 1
Pg. 18-20
(Jan 03 2012)
ISSN: 0376-2491 [Print] China |
PMID | 22490651
(Publication Type: English Abstract, Journal Article, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Abortion, Incomplete
(drug therapy, etiology)
- Abortion, Induced
(adverse effects)
- Double-Blind Method
- Female
- Humans
- Mifepristone
(therapeutic use)
- Pregnancy
|